Cargando…

Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics

PURPOSE: This survey of Italian psychiatrists was conducted to better define drivers of schizophrenia treatment choice in real-life practice, particularly for use of long-acting injectable (LAI) antipsychotics. METHODS: Between October 15 and December 15, 2014, 1,000 surveys were sent to psychiatris...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Bartolomeis, Andrea, Fagiolini, Andrea, Vaggi, Marco, Vampini, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714729/ https://www.ncbi.nlm.nih.gov/pubmed/26811682 http://dx.doi.org/10.2147/NDT.S96214

Ejemplares similares

Achieving long-term goals through early personalized management of schizophrenia: expert opinion on the role of a new fast-onset long-acting injectable antipsychotic
por: Vita, Antonio, et al.
Publicado: (2023)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
por: Pietrini, Francesco, et al.
Publicado: (2019)

Patient-psychiatrist discordance and drivers of prescribing long-acting injectable antipsychotics for schizophrenia management in the real-world: a point-in-time survey
por: Keenan, Alexander, et al.
Publicado: (2022)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery
por: Arango, Celso, et al.
Publicado: (2023)

Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
por: Arango, Celso, et al.
Publicado: (2023)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald, Heather M, et al.
Publicado: (2021)

Attitudes of Italian Psychiatrists Toward the Evaluation of Physical Comorbidities and Sexual Dysfunction in Patients With Schizophrenia. Implications for Clinical Practice
por: Monteleone, Palmiero, et al.
Publicado: (2019)

Weight Gain, Schizophrenia and Antipsychotics: New Findings from Animal Model and Pharmacogenomic Studies
por: Panariello, Fabio, et al.
Publicado: (2011)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2019)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10
por: Tatini, Lorenzo, et al.
Publicado: (2021)

Psychiatrists' Attitudes toward Metabolic Adverse Events in Patients with Schizophrenia
por: Sugawara, Norio, et al.
Publicado: (2014)

Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context
por: Caresano, Chiara, et al.
Publicado: (2014)

Psychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey
por: Olivares, Jose Manuel, et al.
Publicado: (2013)

Antipsychotic prescribing of consultant forensic psychiatrists working in different levels of secure care with patients with schizophrenia
por: Machin, Anna, et al.
Publicado: (2017)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

PM399. Attitudes toward antipsychotic long-acting injections among patients with Schizophrenia in Japan.
por: Kudo, Shuhei, et al.
Publicado: (2016)

Schizophrenia Synaptic Pathology and Antipsychotic Treatment in the Framework of Oxidative and Mitochondrial Dysfunction: Translational Highlights for the Clinics and Treatment
por: De Simone, Giuseppe, et al.
Publicado: (2023)

Consultant psychiatrists’ experiences of and attitudes towards shared decision making in antipsychotic prescribing, a qualitative study
por: Shepherd, Andrew, et al.
Publicado: (2014)

THE NARCOTIC DRUGS ACT AND THE PSYCHIATRIST
por: Channabasavanna, S.M.
Publicado: (1986)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

Dysregulated Signaling at Postsynaptic Density: A Systematic Review and Translational Appraisal for the Pathophysiology, Clinics, and Antipsychotics’ Treatment of Schizophrenia
por: de Bartolomeis, Andrea, et al.
Publicado: (2023)

Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey
por: Liu, Chun-Hao, et al.
Publicado: (2018)

A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
por: Correll, C. U., et al.
Publicado: (2022)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
por: Correll, C. U., et al.
Publicado: (2022)

Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists’ Attitudes in Taiwan
por: Yen, Ko, et al.
Publicado: (2022)

“Antipsychotics Basket of the last decade for a psychiatrist: Within and Beyond!”
Publicado: (2022)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations
por: Rossi, Giuseppe, et al.
Publicado: (2012)

Newer antipsychotics and the rabbit syndrome
por: Catena Dell'Osso, Mario, et al.
Publicado: (2007)

Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis
por: Polese, Daniela, et al.
Publicado: (2019)

Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review
por: de Bartolomeis, Andrea, et al.
Publicado: (2022)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
por: Riboldi, Ilaria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7ngpgt1p57v2qlsjp3c14mpe3r